ArticleAmerican journal of preventive cardiology2026
Association of high-sensitivity cardiac troponin T with all-cause and cardiovascular mortality in a mobile cohort of older adults aged 70 to 95 years - Results from the AugUR study.
Article in American journal of preventive cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: It remains unclear whether high-sensitivity cardiac troponin T (hsTnT) independently predicts mortality in older adults. Objective: To estimate mortality rate and association of hsTnT with all-cause and cardiovascular death in the older, mobile population. Methods: This analysis was conducted in 2055 subjects of the AugUR-study, a prospective population-based cohort study in individuals aged 70 years and older with up to 10-year mortality follow-up. We used Cox proportional hazard models to estimate hazard ratios (HR) and 95% confidence intervals (CI) for association of hsTnT with all-cause, cardiovascular, non-cardiovascular and premature mortality risk. Association results of hsTnT with mortality were reported for tertiles and per 1 standard deviation (SD) of log-transformed values. Results: Participants were 70 to 95 years old with 48% men and 56% with prevalent cardiovascular disease (CVD). In a median follow-up period of 6.0 years, 385 (113 cardiovascular) deaths were recorded. For all-cause mortality, HR was 1.66 [95%CI=1.49-1.85] after adjustment for age and sex (p-value<0.001). For cardiovascular mortality, the effect was more pronounced (HR=2.17 [95%CI=1.79-2.63]; Conclusion: Elevated levels of hsTnT were associated with increased cardiovascular and non-cardiovascular mortality risk in an old-aged population. Measurement of hsTnT in subjects with prevalent CVD may help identify individuals at high risk for mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.